Literature DB >> 26179554

Colonic bacterial composition in Parkinson's disease.

Ali Keshavarzian1,2,3,4, Stefan J Green5,6, Phillip A Engen1, Robin M Voigt1, Ankur Naqib5, Christopher B Forsyth1,7, Ece Mutlu1, Kathleen M Shannon8.   

Abstract

INTRODUCTION: We showed that Parkinson's disease (PD) patients have alpha-synuclein (α-Syn) aggregation in their colon with evidence of colonic inflammation. If PD patients have altered colonic microbiota, dysbiosis might be the mechanism of neuroinflammation that leads to α-Syn misfolding and PD pathology.
METHODS: Sixty-six sigmoid mucosal biopsies and 65 fecal samples were collected from 38 PD patients and 34 healthy controls. Mucosal-associated and feces microbiota compositions were characterized using high-throughput ribosomal RNA gene amplicon sequencing. Data were correlated with clinical measures of PD, and a predictive assessment of microbial community functional potential was used to identify microbial functions.
RESULTS: The mucosal and fecal microbial community of PD patients was significantly different than control subjects, with the fecal samples showing more marked differences than the sigmoid mucosa. At the taxonomic level of genus, putative, "anti-inflammatory" butyrate-producing bacteria from the genera Blautia, Coprococcus, and Roseburia were significantly more abundant in feces of controls than PD patients. Bacteria from the genus Faecalibacterium were significantly more abundant in the mucosa of controls than PD. Putative, "proinflammatory" Proteobacteria of the genus Ralstonia were significantly more abundant in mucosa of PD than controls. Predictive metagenomics indicated that a large number of genes involved in metabolism were significantly lower in the PD fecal microbiome, whereas genes involved in lipopolysaccharide biosynthesis and type III bacterial secretion systems were significantly higher in PD patients.
CONCLUSION: This report provides evidence that proinflammatory dysbiosis is present in PD patients and could trigger inflammation-induced misfolding of α-Syn and development of PD pathology.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  a-synuclein; colonic mucosa and feces; dysbiosis; microbiota; putative butyrate producing short-chain fatty acids

Mesh:

Substances:

Year:  2015        PMID: 26179554     DOI: 10.1002/mds.26307

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  329 in total

1.  Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

Authors:  Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

2.  α-Synuclein in gut endocrine cells and its implications for Parkinson's disease.

Authors:  Rashmi Chandra; Annie Hiniker; Yien-Ming Kuo; Robert L Nussbaum; Rodger A Liddle
Journal:  JCI Insight       Date:  2017-06-15

3.  Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.

Authors:  Natalia Palacios; Katherine C Hughes; Emanuele Cereda; Michael A Schwarzschild; Alberto Ascherio
Journal:  Mov Disord       Date:  2018-09-14       Impact factor: 10.338

4.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

5.  Considerations When Designing a Microbiome Study: Implications for Nursing Science.

Authors:  Katherine A Maki; Ana F Diallo; Mark B Lockwood; Alexis T Franks; Stefan J Green; Paule V Joseph
Journal:  Biol Res Nurs       Date:  2018-11-08       Impact factor: 2.522

Review 6.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

7.  Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder.

Authors:  Tanya T Nguyen; Tomasz Kosciolek; Lisa T Eyler; Rob Knight; Dilip V Jeste
Journal:  J Psychiatr Res       Date:  2018-01-31       Impact factor: 4.791

8.  Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites.

Authors:  Zhi-Lan Zhou; Xue-Bing Jia; Meng-Fei Sun; Ying-Li Zhu; Chen-Meng Qiao; Bo-Ping Zhang; Li-Ping Zhao; Qin Yang; Chun Cui; Xue Chen; Yan-Qin Shen
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 9.  Psychobiotics: The Next-Generation Probiotics for the Brain.

Authors:  Richa Sharma; Deesha Gupta; Rekha Mehrotra; Payal Mago
Journal:  Curr Microbiol       Date:  2021-01-04       Impact factor: 2.188

10.  Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.

Authors:  Zachary D Wallen; Mary Appah; Marissa N Dean; Cheryl L Sesler; Stewart A Factor; Eric Molho; Cyrus P Zabetian; David G Standaert; Haydeh Payami
Journal:  NPJ Parkinsons Dis       Date:  2020-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.